Business Trip
Business Trip explores the frontiers of brain and mental health through conversations with founders, investors, and researchers at the intersection of neuroscience and technology.
Business Trip
Startups, philanthropy, billionaires, academia, neuromodulation, psychedelics, AI and new therapies in bipolar, autism, and Parkinson’s with Rob Malenka
•
Greg Kubin & Matias Serebrinsky
•
Season 1
•
Episode 68
Matias interviews Rob Malenka.
In this episode, we discuss:
- Why progress in psychiatry is slow because the brain is the most complex organ and many disorders are highly heterogeneous
- The bottlenecks including weak replicability in research, academic politics, perverse incentives, and pharma’s avoidance of neuropsychiatry
- How breakthroughs require early detection, rigorous science, and bridging academia with biotech through venture philanthropy
- How success depends on mission-driven, ethical people who align science, capital, and patient impact.
- The opportunities in neuromodulation, data-driven precision medicine, and combination therapies.
Credits:
Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky
Produced by Caitlin Ner & Nico V. Rey
Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank